论文部分内容阅读
目的探讨托特罗定联合塞来昔布治疗良性前列腺增生(BPH)术后膀胱痉挛的疗效。方法将BPH患者256例随机均分为两组,术后口服托特罗定和塞来昔布(联合用药组)和单用托特罗定(托特罗定组)。记录术后出现膀胱痉挛的例数、痉挛持续时间及视觉模拟疼痛评分。结果联合用药组术后第2、3天膀胱痉挛次数分别为(1.25±0.71)次和(1.05±0.69)次,少于托特罗定组的(1.63±0.83)次和(1.38±0.78)次(P<0.05);膀胱痉挛持续时间分别为(7.85±2.91)min、(6.43±3.32)min,亦少于托特罗定组的(11.24±3.11)min、(9.43±3.63)min(P<0.05)。结论联合应用托特罗定和塞来昔布治疗经尿道前列腺术后膀胱痉挛的效果优于单用托特罗定。
Objective To investigate the curative effect of tolterodine combined with celecoxib on bladder spasm after benign prostatic hyperplasia (BPH). Methods 256 patients with BPH were randomly divided into two groups. After oral administration of tolterodine and celecoxib (combination group) and only tolterodine (group of tolterodine). The number of postoperative bladder spasms, spastic duration and visual analogue pain score were recorded. Results The number of bladder spasm in the combination group was (1.25 ± 0.71) times and (1.05 ± 0.69) times on the 2nd and 3rd postoperative days respectively, less than that of the tolterodine group (1.63 ± 0.83) and (1.38 ± 0.78) (7.85 ± 2.91) min and (6.43 ± 3.32) min respectively, which was also lower than that of tolterodine group (11.24 ± 3.11) min and (9.43 ± 3.63) min respectively (P <0.05). The duration of bladder spasm was P <0.05). Conclusions Combination of tolterodine and celecoxib is superior to tolterodine alone in the treatment of post-transurethral bladder spasm.